MBIO - MUSTANG BIO, INC.

1.27
-0.080   -6.299%

Share volume: 37,634
Last Updated: 04-08-2025
Pharmaceutical Products/Pharmaceutical Preparations: 0.05%

PREVIOUS CLOSE
CHG
CHG%
$1.35
-0.08
-0.06%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
23%
Profitability 0%
Dept financing 25%
Liquidity 40%
Performance 40%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
4.10%
1 Month
-15.33%
3 Months
394.93%
6 Months
487.96%
1 Year
87.87%
2 Year
-60.31%
Key data
Stock price
$1.27
P/E Ratio 
0.00
DAY RANGE
$1.26 - $1.37
EPS 
-$2.41
52 WEEK RANGE
$0.11 - $6.70
52 WEEK CHANGE
$144.42
MARKET CAP 
8.457 M
YIELD 
N/A
SHARES OUTSTANDING 
36.387 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
04-15-2025
BETA 
37.22
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$115,189
AVERAGE 30 VOLUME 
$70,498
Company detail
CEO: Manuel Litchman
Region: US
Website: mustangbio.com
Employees: 100
IPO year: 2017
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. The company develops MB-107 and MB-207, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition.

Recent news
loading